The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One of the systems that have gained attention in recent times is the gut–brain axis. Although numerous peptides participate in this axis, glucagon-like peptide-1 (GLP-1) plays a central role. GLP-1 is a crucial anorexigenic peptide, with potent abilities to reduce food intake and body weight. The physiological complexity of GLP-1 entails glucose homeostasis, gastrointestinal motility, and the release of insulin and glucagon. As reviewed in this study, acute or repeated treatment with GLP-1 receptor (GLP-1R) agonists decreases alcohol consumption in rodents. Moreover, the abilities of alcohol to promote hyperlocomotion, dopamine release in the nucleus accumbens, and reward in the conditioned place preference paradigm are all suppressed by GLP-1R ligands. Moreover, activation of GLP-1R suppresses the motivation to consume alcohol, alcohol-seeking behaviors, and relapse drinking in male rodents. Similarly, abstinence symptoms experienced during alcohol withdrawal are attenuated by activation of the GLP-1 pathway. On a similar note, the activation of GLP-1 receptors within areas of the brain that are processing reward modulates these alcohol-related responses. Another area that is crucial for this ability is the nucleus of the solitary tract, which is where GLP-1 is produced and from which GLP-1-containing neurons project to areas of reward. These findings may have clinical relevance as AUD is associated with polymorphisms in GLP-1-related genes. Although a GLP-1R agonist does not alter alcohol intake in AUD patients, it reduces this consumption in a sub-population of obese AUD individuals. Given the uncertainty of this outcome, additional clinical studies of obese AUD patients should explore the effects of the GLP-1R agonists on alcohol intake and body weight. Furthermore, GLP-1 receptors modulate the behavioral and neurochemical responses to addictive drugs. Taken together, these preclinical and clinical findings imply that the GLP-1 pathway plays a role in the complex mechanisms regulating alcohol and drug consumption patterns, unveiling a novel aspect of addiction medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal models support that GLP-1RA treatment causally reduces alcohol intake, and GLP-1RAs may dampen the release of dopamine in the nucleus accumbens in response to alcohol intake as well as increase the breakdown of dopamine [17,84,85,86].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 7×
“Moreover, GLP-1 production has been shown in some neurons of the nucleus of the solitary tract (NTS) in the brain stem [for a review, see Holst (2007)].”
BackgroundInfluentialA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“These incretin functions have led to the approval of GLP-1R agonists for the treatment of type II diabetes (Kreymann et al., 1987).”
BackgroundAlcohol, liver disease and the gut microbiota
Bajaj, J. S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0099-1 · Cited by 697 · cited 1×
“Indeed, alcohol and GLP-1R agonists modify the gut microbiota composition [for reviews, see Bajaj (2019); Sayehmiri et al. (2022)].”
BackgroundREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 3×
“Later on, in the addiction cycle, relapse drinking after alcohol withdrawal is an important aspect of AUD, and this can be modeled using the alcohol deprivation test in rats (Sanchis-Segura and Spanagel, 2006).”
BackgroundCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 2×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundRinaman, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.059 · Cited by 311 · cited 1×
“One circuit of interest is the GLP-1-producing neurons from the NTS that target the LDTg, VTA, and NAc (Figure 2) (Rinaman, 2010).”
BackgroundKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 3×
“Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baas…”
BackgroundKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 2×
“In this study, exenatide does not alter alcohol intake in AUD patients who were of regular weight (Klausen et al., 2022).”
Background
Research works printed but not linked: 1
- Kalra, 2011, Change in alcohol consumption following liraglutide initiation: A real life experience, 2019
Cited by
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2295397 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“One of the important aspects of the anorectic effects of GLP-1RAs is their effect on the reward system 225,226 .”
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
Metadata
- Authors
- Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Jerlhag, Elisabet
- ORCID
- Jerlhag, Elisabet
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-30
- Volume
- 14
- Pages
- 1063033-1063033
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10097922
- OpenAlex
- W4361280631
- Cited by
- 80
- References
- 80
- Citations by year
- 2026: 17 · 2025: 36 · 2024: 20 · 2023: 7
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet
- Hjärnfonden
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, alcoholism, addiction, gut-brain axis, alcohol withdrawal, nucleus tractus solitarius, nucleus accumbens dopamine, conditioned place preference, alcohol relapse, obesity, genetic polymorphism, drug addiction, anorexigenic peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. https://app.cochat.ai/papers/10.3389/fphar.2023.1063033
- The paper
- Jerlhag, E. (2023). The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1063033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.